Prostate cancer is staged using a combination of five factors: the size and extent of the tumor, whether it has spread to lymph nodes, whether it has reached distant organs, your PSA blood level at diagnosis, and a Grade Group score based on how the cancer cells look under a microscope. These five pieces of information are combined into an overall stage ranging from I (earliest) to IV (most advanced). The system used is the AJCC TNM staging system, and understanding it can help you make sense of a diagnosis and the treatment conversations that follow.
The Five Factors That Determine Your Stage
Each factor captures something different about the cancer, and no single one tells the full story. Together, they give doctors a detailed picture of how far the disease has progressed and how aggressive it’s likely to be.
T (Tumor): Describes how large the primary tumor is and whether it has grown beyond the prostate itself. A T1 tumor is too small to feel on a physical exam or see on imaging. T2 means the tumor can be felt but is still contained within the prostate. T3 indicates growth outside the prostate wall or into the seminal vesicles. T4 means the cancer has invaded nearby structures beyond the seminal vesicles, such as the bladder or pelvic wall.
N (Nodes): Indicates whether cancer cells have reached nearby lymph nodes. N0 means no lymph node involvement. N1 means cancer cells are present in lymph nodes near the prostate.
M (Metastasis): Tells you whether the cancer has spread to distant parts of the body, such as bones or distant lymph nodes. M0 means no distant spread. M1 means the cancer has metastasized.
PSA level: Your PSA blood level at the time of diagnosis is grouped into three tiers. Low is below 10 ng/mL. Intermediate is between 10 and 20 ng/mL. High is above 20 ng/mL. Higher PSA levels push the overall stage higher, even if the tumor itself is small.
Grade Group: This is based on how abnormal the cancer cells look under a microscope, scored from 1 to 5. It replaced the older Gleason score as the primary grading tool, though both are still reported. A higher Grade Group means the cancer is more likely to grow and spread quickly.
How Grade Groups Work
When a pathologist examines your biopsy tissue, they assess how much the cancer cells resemble normal prostate tissue. Normal prostate tissue forms well-organized glands. Cancer cells that still form recognizable glands are considered lower grade. Cells that have lost their gland structure entirely are higher grade.
- Grade Group 1 (Gleason score 6 or lower): Cells form individual, well-shaped glands. This is the lowest grade and the slowest growing.
- Grade Group 2 (Gleason score 3+4=7): Mostly well-formed glands with a smaller portion of poorly formed or fused glands.
- Grade Group 3 (Gleason score 4+3=7): The reverse of Group 2. Mostly poorly formed glands with a smaller portion of well-formed ones. Despite having the same total Gleason score of 7, this distinction matters because Group 3 behaves more aggressively than Group 2.
- Grade Group 4 (Gleason score 8): Cells are almost entirely poorly formed, fused, or lacking normal gland structure.
- Grade Group 5 (Gleason scores 9-10): Gland formation is essentially absent, sometimes with tissue death visible. This is the most aggressive pattern.
Overall Stage Groups: I Through IV
Once all five factors are determined, they’re combined into a single stage. Here’s what each one generally means.
Stage I: The cancer is small, can’t be felt on exam, has a Grade Group of 1, and a PSA below 10. This is the most favorable scenario. The tumor is entirely within the prostate and shows no signs of aggressive behavior.
Stage II (IIA, IIB, IIC): The cancer is still confined to the prostate, but one or more factors are slightly more concerning. In Stage IIA, the PSA has risen to between 10 and 20 while the Grade Group remains 1. In Stages IIB and IIC, the Grade Group may be 2 or 3, or the tumor may be larger or felt on both sides of the prostate. PSA stays below 20 in all Stage II categories.
Stage III (IIIA, IIIB, IIIC): This is where things shift. Stage IIIA means the PSA has exceeded 20, regardless of the tumor size. Stage IIIB indicates the tumor has physically grown beyond the prostate wall or into the seminal vesicles. Stage IIIC is assigned when the Grade Group reaches 4 or 5, signaling highly aggressive cell patterns, regardless of tumor size or PSA. In Stage III, the cancer has not yet spread to lymph nodes or distant organs.
Stage IV (IVA, IVB): Stage IVA means the cancer has spread to nearby lymph nodes. Stage IVB means it has metastasized to distant sites, most commonly the bones. PSA and Grade Group can be any value at this stage.
Clinical Staging vs. Pathological Staging
You may see your stage written with a lowercase “c” or “p” in front of it. Clinical staging (cTNM) is based on what doctors can learn before any surgery: the digital rectal exam, PSA blood test, biopsy results, and imaging scans like MRI or bone scans. This is the stage most people receive at diagnosis.
Pathological staging (pTNM) happens after surgery, when a pathologist can examine the entire removed prostate and any sampled lymph nodes under a microscope. Pathological staging is more precise because it reveals details imaging might miss, like microscopic spread beyond the prostate capsule or cancer cells in lymph nodes that appeared normal on a scan. Not everyone undergoes surgery, so not everyone receives a pathological stage.
Risk Groups Add Another Layer
Beyond the numbered stages, doctors often classify prostate cancer into risk groups that guide treatment decisions more directly. These range from very low risk to very high risk.
Very-low-risk cancers are small, can’t be felt, are found in only a small area of the prostate, have a Grade Group of 1, and a PSA below 10. These are often candidates for active surveillance rather than immediate treatment. Low-risk cancers share those Grade Group and PSA characteristics but may be slightly larger.
Intermediate-risk cancers can be felt on exam or seen on imaging. They may involve more than half of one side of the prostate or both sides, have a Grade Group of 2 or 3, or a PSA between 10 and 20. This group is further split into favorable and unfavorable categories, which influences whether active surveillance remains an option.
High-risk cancers have one of the following: growth beyond the prostate, a Grade Group of 4 or 5, or a PSA above 20. Very-high-risk cancers may have spread into the seminal vesicles or adjacent structures, show the most aggressive cell patterns on biopsy, or have multiple high-risk features present at the same time.
Genomic Tests in Staging Decisions
In some cases, particularly when the staging and risk group land in a gray zone, doctors may order a genomic test on the biopsy tissue. These tests analyze the activity of specific genes within the cancer cells to predict how aggressively the cancer is likely to behave. One widely used test produces a score that categorizes risk as lower (below 0.45), average (0.45 to 0.60), or higher (above 0.60). These results don’t change the formal TNM stage, but they can tip the balance between active surveillance and treatment, or between less and more aggressive treatment approaches.
What Staging Means for Survival
Prostate cancer caught before it spreads to distant organs has an exceptionally favorable outlook. According to data from the National Cancer Institute’s SEER database covering 2016 through 2022, the five-year relative survival rate for localized prostate cancer (confined to the prostate) is 100%. The same is true for regional disease, meaning cancer that has spread to nearby lymph nodes. Once the cancer has metastasized to distant organs, the five-year survival rate drops to about 40%. These numbers reflect outcomes across all treatment types and patient populations, so individual outcomes vary based on specific circumstances, overall health, and treatment choices.
The sharp difference between localized and distant survival rates is a big part of why staging matters so much. It shapes the urgency and intensity of treatment, determines which options are on the table, and gives you a realistic framework for what to expect.